Archived AES Symposia 2004
Genetics and Epilepsy Syndromes
Program Length: 7 hrs 26 min
The 2004 AES Annual Course, "Genetics and Epilepsy Syndromes," will focus on defining the state of the art in genetic information about human epilepsy. Following an initial review of the genetics of complex diseases, syndromes of generalized and focal epilepsies affecting children and adults will be reviewed with special attention to their genetic basis. Use of family history, issues of drug resistance, and genetic insights into the basic mechanisms of epilepsy will be discussed. The course will feature major talks by leaders in the field, and will utilize focused case presentations by leading clinicians to illustrate clinical issues that arise in the evaluation of patients and to demonstrate the utility of genetic information.
At the conclusion of this activity, participants should be able to:
- State the principles of identifying the genetic basis of diseases that manifest complex inheritance
- Describe and recognize genetically determined epilepsies in clinical practice
- Identify the issues involved in relating genetic abnormalities to the pathophysiology of epilepsy
- Describe potential biochemical causes of anti-convulsant drug resistance and apply this information to clinical practice.
Physicians involved in the evaluation and treatment of epilepsy, including neurologists, neurosurgeons and psychiatrists, epilepsy and neurophysiology fellows, residents and other healthcare professionals.
Co-Chairs: Andrew J. Cole, M.D., FRCP(C) & Orrin Devinsky, M.D.
- Case Presentation #1 – Migraine and Epilepsy
Edward B. Bromfield, M.D.
- Analysis of Complex Genetic Diseases
Ruth Ottman, Ph.D.
- Case Presentation #2 – Refractory Primary Generalized Epilepsy
Mohamad Mikati, M.D.
- Primary Generalized Epilepsy Syndromes
Samuel F. Berkovic, M.D.
- Case Presentation #3 – Linear Nevus Syndrome
Prakash Kotagal, M.D.
- Neurocutaneous Syndromes and Epilepsy: Issues in Diagnosis and Management
Helen J. Cross, M.D.
- Case Presentation #4 – Genetic Counseling in the Epilepsy Clinic: Patients with IGEs
Melodie R. Winawer, M.D., M.S.
- Genetic Epidemiology and Seizure Susceptibility
Shlomo Shinnar, M.D., Ph.D.
- Case Presentation #5 – Response to Anti-epileptic Drug Therapy: Winners and Losers
Martin J. Brodie, M.D.
- Genetics of Drug Resistance
Sanjay M. Sisodiya, M.D.
- Case Presentation #6 – GEFS+
Blanca R. Vazquez, M.D.
- Neonatal Syndromes and GEFS+: Clinical Consideration
Ingrid E. Scheffer, Ph.D., FRACP
- Neonatal Syndromes and GEFS+: Mechanistic Considerations
Daniel L. Burgess, Ph.D.
- Case Presentation #8 – Familial Temporal Lobe Epilepsy with Auditory Features
Fernando Cendes, M.D., Ph.D.
- Genetic Focal Epilepsies: State of the Art and Path to the Future
Frederick Andermann, M.D., FRCP(C)
This program and its re-purposing on the AES Web site with CME credit is supported in part by an educational grant from Ortho-McNeil Pharmaceutical, Inc.
Dr. Andermann has indicated that he has no relationships to disclose.
Dr. Berkovic receives grants/research support from National Health and Medcial Research Council of Australia, UCB Pharma, Janssen-Cilag, Pfizer Inc. He is a consultant for Bionomics, Ltd., and Athena Diagnostics.
Dr. Brodie receives grants/research support from UCB Pharma, Pfizer Inc and Cephalon. He is a consultant for UCB Pharma, Pfizer Inc., Johnson & Johnson, Novartis Pharmaceuticals, Acorda, Desitin, Eisai Inc., Ivax and Schwarz Pharma.
Dr. Bromfield receives honorarium from Abbott Laboratories, Pfizer Inc., Novartis Pharmaceuticals and UCB Pharma.
Dr. Burgess has indicated that he has no relationships to disclose.
Dr. Cendes has indicated that he has no relationships to disclose.
Dr. Cross receives grants/research support from Janssen-Cilag and SHS. She is a consultant for Janssen-Cilag, UCB Pharma and Eisai Inc. She has received other financial/material support from UCB Pharma and Janssen-Cilag.
Dr. Kotagal has received other financial/material support from Speakers Bureau and Ortho-McNeil Pharmaceutical, Inc.
Dr. Mikati receives grants/research support from GlaxoSmithKline and Janssen.
Dr. Noebels has indicated that he has no relationships to disclose.
Dr. Ottman has indicated that she has no relationships to disclose.
Dr. Scheffer receives grants/research support from Bionomics. She is a consultant for Bionomics and Athena Diagnostics.
Dr. Shinnar has indicated that he has no relationships to disclose.
Dr. Sisodiya has indicated that he has no relationships to disclose.
Dr. Vazquez receives grants/research support from GlaxoSmithKline, UCB Pharma, Ortho-McNeil Pharmaceutical, Inc., Abbott Laboratories, Pfizer Inc. and Novartis Pharmaceutical. She is a consultant for GlaxoSmithKline, UCB Pharma, Ortho-McNeil Pharmaceutical, Abbott Laboratories, Pfizer Inc. and Novartis Pharmaceutical. She receives honorarium from GlaxoSmithKline, UCB Pharma, Ortho-McNeil Pharmaceutical, Abbott Laboratories, Pfizer Inc. and Novartis Pharmaceutical.
Dr. Winawer receives grants/research support from NINDS.
Discussion of Unlabeled/Unapproved Uses
This educational activity may include references to the use of products for indications not approved by the FDA. These are noted in the faculty disclosure forms and will be acknowledged during their presentations. Opinions expressed with regard to the unapproved use of products are solely those of the faculty and are not endorsed by the American Epilepsy Society. The American Epilepsy Society adheres to the ACCME’s Essential Areas and Policies regarding industry support of continuing medical education and disclosure by faculty of commercial relationships, if any, will be made at the start of the presentation.